References
- Tatro J. B., Atkins M., Mier J. W., Hardarson S., Wolfe H., Smith T., Entwistle M. L., Reichlin S. Melanotropin receptors demonstrated in situ in human melanoma. J. Clin. Invest. 1990; 85: 1825–1832
- Lunec J., Pieron C., Thody A. J. MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma. Melanoma Res. 1992; 2: 5–12
- Bard D. R., Knight C. G., Page-Thomas D. P. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br. J. Cancer 1990; 62: 919–922
- Wraight E. P., Bard D. R., Maughan T. S., Knight C. G., Page-Thomas D. P. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br. J. Radiol. 1992; 65: 112–118
- Bard D. R., Wraight E. P., Knight C. G. BisMSHDTPA: A potential imaging agent for malignant melanoma. Ann. NY Acad. Sci. 1993; 680: 451–453
- Sawyer T. K., Sanfilippo P. J., Hruby V. J., Engel M. H., Heward C. B., Burnett J. B., Hadley M. E. 4-Norleucine, 7-d-phenylalanine-α-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. USA 1980; 77: 5754–5758
- Hadley M. E., Abdel-Malek Z. A., Marwan M. M., Kreutzfeld K. L., Hruby V. J. [Nle4,d-Phe7]-α-MSH: A superpotent melanotropin that “irreversibly” activates melanoma tyrosinase. Endocr. Res. 1985; 11: 157–170
- Al-Obeidi F., Hruby V. J., Castrucci A. M., Hadley M. E. Design of potent linear alpha-melanotropin 4–10 analogues modified in positions 5 and 10. J. Med. Chem. 1989; 32: 174–179
- Hruby V. J., Sharma S. D., Toth K., Jaw J. Y., Al-Obeidi F., Sawyer T. K., Hadley M. E. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann. NY Acad. Sci. 1993; 680: 51–63
- Atherton E., Sheppard R. C. “Solid Phase Peptide Synthesis, a Practical Approach”. IRL Press, Oxford 1989
- Bernatowicz M. S., Daniels S. B., Köster H. A comparison of acid labile linkage agents for the synthesis of peptide C-terminal amides. Tetrahedron Lett 1989; 30: 4645–4647
- Bard D. R., Knight C. G., Page-Thomas D. P., Wraight E. P., Maughan T. S. The use of derivatives of α-MSH for targeting to melanomas in vivo. “Targeting of Drugs 3: The Challenge of Peptides and Proteins”, G. Gregoriadis, et al. Plenum, New York 1992; 1–8
- Gabriel T. F. A simple, rapid method for converting a peptide from one salt form to another. Peptide Protein Res. 1987; 30: 40–43
- , Deleted in proof
- Tatro J. B. Melanotropin receptors of the brain. “Receptors: Model Systems and Specific Receptors”, P. M. Conn. Academic Press, New York/London 1993; 87–104
- Markwell M. A. K. A new solid-state reagent to iodinate proteins. Anal. Biochem. 1982; 125: 427–432
- Pawelek J. M., Wong G., Sansone M., Morowitz J. 1973
- Pawelek J. M., Wong G., Sansone M., Morowitz J. Molecular controls in mammalian pigmentation. Yale J. Biol. Med. 1973; 46: 430–443
- Lande S., Pawelek J., Lerner A. B., Emanuel J. R. Assay of melanotropoic peptides in an in vitro mammalian system. J. Invest. Dermatol. 1981; 77: 244–245
- Panasci L. C., McQuillan A., Kaufman M. Biological activity, binding and metabolic fate of Ac-[Nle4,d-Phe7]α-MSH(4–11)NH2 with the Fl variant of B16 melanoma cells. J. Cell Physiol. 1987; 132: 97–103
- Eberle A. N. “The Melanotropins: Chemistry, Physiology and Mechanisms of Action,”. Karger, Basel 1988; 173–209
- Adams G., Olivier G. W. J., Branch S. K., Moss S. H., Notarianni L. J., Pouton C. W. Evidence for the internalization of [125I-TYR2, NLE4, α-PHE7)α-MSH following binding to the MSH receptor of B16 murine melanoma cells. Ann. NY Acad. Sci. 1993; 680: 440–441
- Deschodt-Lanckman M., Vanneste Y., Loir B., Michel A., Libert A., Ghanem G., Lejeune F. Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by human melanoma cells in culture. Int. J. Cancer 1990; 46: 1124–1130
- Marks N., Stern F., Kastin A. J. Biodegradation of α-MSH and derived peptides by rat brain extracts and rat and human serum. Brain Res. Bull. 1976; 1: 591–593
- Bard D. R., Knight C. G., Wraight E. P., Van Beeumen J., Deveese B., Jacquemotte F. The use of MSH derivatives for targeting to melanomas. “Targeting of Drugs 4: Advances in System Constructs”, G. Gredoriadis, et al. Plenum, New York 1994; 53–59
- Gordon A. H. The role of lysosomes in protein catabolism. “Lysosomes in Biology and Pathology”, J. T. Dingle. North-Holland, Amsterdam 1973; Vol. 3: 89–137